| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,662,826 |
|
|
|
Indirect Value
|
$10,165,498 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$59,828,324 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 55.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-05-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
16,405 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
OE |
$21.25 |
$2,828,500 |
D/D |
100,000 |
78,377 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
D |
$567.63 |
$32,865,209 |
D/D |
(57,899) |
64,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-06 |
4 |
S |
$562.37 |
$11,260,068 |
D/D |
(20,000) |
44,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-09 |
4 |
S |
$558.37 |
$12,377,559 |
D/D |
(22,101) |
22,029 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-12-16 |
4 |
OE |
$52.03 |
$99,950 |
D/D |
1,921 |
27,594 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2016-02-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500 |
40,470 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2016-11-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,876 |
23,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-01 |
4 |
OE |
$145.70 |
$2,091,724 |
D/D |
10,544 |
30,814 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-01 |
4 |
D |
$464.98 |
$3,595,225 |
D/D |
(7,732) |
26,762 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-02 |
4 |
AS |
$466.33 |
$1,348,314 |
D/D |
(2,812) |
23,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-14 |
4 |
OE |
$21.25 |
$431,269 |
D/D |
20,295 |
44,245 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-14 |
4 |
D |
$475.56 |
$5,577,368 |
D/D |
(11,728) |
32,517 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-15 |
4 |
AS |
$462.72 |
$4,013,177 |
D/D |
(8,567) |
23,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-21 |
4 |
OE |
$30.63 |
$612,600 |
D/D |
20,000 |
43,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-21 |
4 |
D |
$510.02 |
$5,964,174 |
D/D |
(11,694) |
32,256 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-22 |
4 |
AS |
$521.70 |
$4,423,332 |
D/D |
(8,306) |
23,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-23 |
4 |
OE |
$30.63 |
$818,924 |
D/D |
26,736 |
58,709 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-23 |
4 |
D |
$293.68 |
$4,501,821 |
D/D |
(15,329) |
43,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-24 |
4 |
S |
$295.09 |
$3,366,092 |
D/D |
(11,407) |
31,973 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-05-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,300 |
21,150 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-08 |
4 |
S |
$330.56 |
$2,492,888 |
D/D |
(7,364) |
22,455 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-25 |
4 |
OE |
$52.03 |
$520,300 |
D/D |
10,000 |
32,455 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-25 |
4 |
D |
$362.75 |
$2,174,324 |
D/D |
(5,994) |
26,461 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-26 |
4 |
S |
$363.58 |
$1,458,467 |
D/D |
(4,006) |
22,455 |
0 |
- |
|
140 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
